{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:38:20Z","timestamp":1792597100141,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA021765"],"award-info":[{"award-number":["P30 CA021765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.cll.2026.07.011","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:22:15Z","timestamp":1787390535000},"page":"733-742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Potential Utility of Model-Informed Precision Dosing in Children"],"prefix":"10.1016","volume":"46","author":[{"given":"Shane J.","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Carl","family":"Panetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.cll.2026.07.011_bib1","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology--drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.cll.2026.07.011_bib2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s40262-023-01293-9","article-title":"Therapeutic drug monitoring of kinase inhibitors in oncology","volume":"62","author":"van der Kleij","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cll.2026.07.011_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.624639","article-title":"Model-informed precision dosing of antibiotics in pediatric patients: a narrative review","volume":"9","author":"Abdulla","year":"2021","journal-title":"Front Pediatr"},{"issue":"4","key":"10.1016\/j.cll.2026.07.011_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40265-025-02152-6","article-title":"From prospective evaluation to practice: model-informed dose optimization in oncology","volume":"85","author":"Agema","year":"2025","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.cll.2026.07.011_bib5","first-page":"719","article-title":"The coming of age of model-informed precision therapeutics for children","volume":"30","author":"Vinks","year":"2025","journal-title":"J Pediatr Pharmacol Therapeut"},{"issue":"4","key":"10.1016\/j.cll.2026.07.011_bib6","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 6","key":"10.1016\/j.cll.2026.07.011_bib7","article-title":"Abstracts from the 57th congress of the international society of paediatric oncology (SIOP) October 20-23, 2025","volume":"72","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.cll.2026.07.011_bib8","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cpt.70209","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2025 update","volume":"119","author":"Maillard","year":"2026","journal-title":"Clin Pharmacol Ther"},{"issue":"18","key":"10.1016\/j.cll.2026.07.011_bib9","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1182\/bloodadvances.2025015928","article-title":"Age-adjusted dosing of fludarabine for lymphodepletion in CAR T-cell therapy: a clinical trial simulation study","volume":"9","author":"Panetta","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.cll.2026.07.011_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s40262-021-01105-y","article-title":"\u201cDe-Shrinking\u201d EBEs: the solution for bayesian therapeutic drug monitoring","volume":"61","author":"Baklouti","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.cll.2026.07.011_bib11","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/psp4.12684","article-title":"A hybrid machine learning\/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors","volume":"10","author":"Hughes","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.cll.2026.07.011_bib12","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/bcp.13901","article-title":"Handling interoccasion variability in model based dose individualization using therapeutic drug monitoring data","volume":"85","author":"Abrantes","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.cll.2026.07.011_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11095-020-02908-7","article-title":"Optimizing predictive performance of Bayesian forecasting for vancomycin concentration in intensive care patients","volume":"37","author":"Guo","year":"2020","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.cll.2026.07.011_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00280-013-2206-x","article-title":"Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments","volume":"72","author":"Pauley","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.cll.2026.07.011_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui","year":"2013","journal-title":"Semin Hematol"},{"issue":"9","key":"10.1016\/j.cll.2026.07.011_bib16","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.1994.12.9.1946","article-title":"Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity","volume":"12","author":"Stewart","year":"1994","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.cll.2026.07.011_bib17","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1200\/JCO.2005.02.097","article-title":"Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach","volume":"23","author":"Santana","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.cll.2026.07.011_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30658","article-title":"Topotecan clearance based on a single sample and a population pharmacokinetic model: application to a pediatric high-risk neuroblastoma clinical trial","volume":"70","author":"Campagne","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"10.1016\/j.cll.2026.07.011_bib19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.annonc.2022.06.010","article-title":"Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study","volume":"33","author":"Groenland","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cll.2026.07.011_bib20","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/1078-0432.CCR-12-1897","article-title":"Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory\/recurrent solid tumors","volume":"19","author":"Navid","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.cll.2026.07.011_bib21","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1111\/cts.13069","article-title":"Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: a simulation study","volume":"14","author":"Panetta","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.cll.2026.07.011_bib22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/jpids\/pix109","article-title":"Individualized empiric vancomycin dosing in neonates using a model-based approach","volume":"8","author":"Frymoyer","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"2","key":"10.1016\/j.cll.2026.07.011_bib23","first-page":"434","article-title":"Bayesian clinical decision support-guided versus clinician-guided vancomycin dosing in attainment of targeted pharmacokinetic parameters in a paediatric population","volume":"75","author":"Hughes","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.cll.2026.07.011_bib24","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1007\/s00431-023-05103-z","article-title":"Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program","volume":"182","author":"Velarde-Salcedo","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"12","key":"10.1016\/j.cll.2026.07.011_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70438","article-title":"Building a beta-lactam model-informed precision dosing service in a Quaternary care children\u2019s hospital","volume":"18","author":"Tang Girdwood","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.cll.2026.07.011_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2026.107809","article-title":"Model-informed cefepime dosing in paediatric patients receiving continuous renal replacement therapy","volume":"67","author":"Morales Junior","year":"2026","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.cll.2026.07.011_bib27","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.6558","article-title":"Development of a web-accessible population pharmacokinetic service-hemophilia (WAPPS-Hemo): study protocol","volume":"5","author":"Iorio","year":"2016","journal-title":"JMIR Res Protoc"},{"issue":"7","key":"10.1016\/j.cll.2026.07.011_bib28","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/jac\/dkab011","article-title":"The case for \u2018conservative pharmacotherapy\u2019","volume":"76","author":"Jorgensen","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cll.2026.07.011_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115421","article-title":"Model-informed precision dosing: state of the art and future perspectives","volume":"215","author":"Minichmayr","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.cll.2026.07.011_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00280-016-3071-1","article-title":"Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours","volume":"78","author":"Goulooze","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cll.2026.07.011_bib31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev-pharmtox-033020-113257","article-title":"Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy","volume":"61","author":"Darwich","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.cll.2026.07.011_bib32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3389\/fphar.2020.00551","article-title":"Model-informed precision dosing of vancomycin in hospitalized children: implementation and adoption at an academic children\u2019s hospital","volume":"11","author":"Frymoyer","year":"2020","journal-title":"Front Pharmacol"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:40:42Z","timestamp":1792593642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271226000818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0272271226000818"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2026.07.011","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Potential Utility of Model-Informed Precision Dosing in Children","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2026.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}